
Please try another search
Surface Oncology, Inc. is a clinical-stage, immuno-oncology company, which is focused on developing immunotherapies that target the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Name | Age | Since | Title |
---|---|---|---|
Robert W. Ross | 47 | 2016 | President, CEO & Director |
David S. Grayzel | 53 | 2014 | Independent Director |
Denice M. Torres | 61 | 2021 | Independent Chairman & Lead Independent Director |
Armen B. Shanafelt | 63 | 2014 | Independent Director |
J. Jeffrey Goater | 47 | 2017 | Director |
Christopher Hunter | - | 2019 | Member of Scientific Advisory Board |
David Tuveson | - | 2019 | Member of Scientific Advisory Board |
F. Stephen Hodi | - | - | Member of Scientific Advisory Board |
Alexander Rudensky | - | 2019 | Member of Scientific Advisory Board |
John Stagg | - | 2019 | Member of Scientific Advisory Board |
Arlene Sharpe | - | 2019 | Member of Scientific Advisory Board |
Ramy Ibrahim | 47 | 2019 | Independent Director |
Laurie D. Stelzer | 54 | 2018 | Independent Director |
Carla Rothlin | - | 2019 | Member of Scientific Advisory Board |
E. John Wherry | - | 2019 | Member of Scientific Advisory Board |
Benjamin J. Hickey | 47 | 2021 | Independent Director |
Charles Elliott Sigal | 71 | 2018 | Independent Member of Scientific Advisory Board & Director |
Carsten Brunn | 52 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review